Leukotriene B4 (LTB4) stimulates the release of cytokines and mediators that participate in tissue inflammation and acts as a chemoattractant for neutrophils, eosinophils and monocytes at the inflammation site.
Aberrant NLRP3 inflammasome activation is at the root of a wide number of conditions, from heart, gastrointestinal, kidney or liver disorders to neuroinflammatory diseases such as Parkinson’s disease or multiple sclerosis. Researchers from Nodthera Ltd. have reported on NT-0796, an NLRP3 inflammasome inhibitor with an in vivo brain penetration profile.
The Korean Research Institute of Bioscience and Biotechnology has synthesized peptides reported to be useful for the treatment of inflammatory disorders.
Anaptysbio Inc. has signed an exclusive license agreement for Centessa Pharmaceuticals plc’s blood dendritic cell antigen 2 (BDCA-2) modulator antibody portfolio, including lead asset CBS-004 (to be renamed ANB-101) and related family of backup antibodies, for the treatment of autoimmune and inflammatory diseases.
The Korean Research Institute of Bioscience and Biotechnology has synthesized peptides reported to be useful for the treatment of inflammatory disorders.
Inhibition of receptor-interacting serine/threonine-protein kinase 2 (RIPK2) has been previously described as a promising strategy for the treatment of inflammatory bowel disease, as RIPK2 is a key player in the signaling leading to bacterial peptidoglycan (PGN)-induced inflammation and it amplifies pro-inflammatory responses in the intestine.
Researchers from Abbvie Inc. have reported on the discovery and optimization of a series of selective tyrosine kinase 2 (TYK2) inhibitors that led to the identification of ABBV-712 as the lead compound.
Novacell Technology Inc. has identified peptides acting as N-formyl peptide receptor 2 (FPR2; FPRL1; LXA4) agonists reported to be useful for the treatment of cancer, inflammatory and immunological disorders.
Bristol Myers Squibb Co. has identified triazole N-linked carbamoyl cyclohexyl acids acting as lysophosphatidic acid LPA1 receptor (LPAR1; EDG2) antagonists reported to be useful for the treatment of fibrosis, cancer, transplant rejection, osteoporosis, inflammatory disorders, neuropathic pain, atherosclerosis and chronic obstructive pulmonary disease, among others.
Nuevolution A/S has synthesized bromodomain-containing protein 4 (Brd4, HUNK1) inhibitors reported to be useful for the treatment of cancer, hypoxia, fibrosis, autoimmune disease, inflammatory disorders and viral infections.
RSS
